foxo4 dri senolytic peptide Buy FOXO4-DRI (Proxofim) Molecular modelling of the FOXO4-TP53
Description
No clinical trials in humans
Barrett supported Higher Education administration and strategic initiatives as a member of an internal consulting team
The more recent STEP UP trial tested a higher dose of 7.2 mg and showed average weight loss of 20.7% at 72 weeks
Early research suggests it may influence certain biological repair pathways
Limitations The review was conducted only using PubMed and hand search
